Revenue Beat Estimates by 6.7% — So Why Did Coty's Stock Fall? Two Reasons
2026-08-21 8:42 AMCosmetics & Perfumes
Overview
Coty posted Q4 FY2026 net revenue of $1.27B, beating consensus by 6.7%, but adjusted EPS of -$0.02 missed the -$0.01 estimate. The stock, up more than 10% in the regular session, fell 4.6% after hours once results were released. A meaningful share of the headline improvement came not from an operating recovery but from the Wella and Gucci Beauty divestitures, and the new interim CEO's guidance covers only half the fiscal year, not the full year.
On August 19, Coty Inc. reported results for the fourth quarter of fiscal 2026 (July 2025–June 2026). Net revenue came in at $1.27B, beating the roughly $1.19B Wall Street expected by 6.7% — on the surface, a beat. Yet the stock, which had climbed more than 10% during the regular session, fell 4.6% in after-hours trading once the results were released, and the decline carried into the next day. Revenue won, so why did the market turn its back? The answer sits just below the headline number — adjusted earnings per share (EPS) of -$0.02 missed the -$0.01 estimate, and a meaningful share of the cash behind this quarter's improvement came not from operations but from two large asset sales.
The Quarter and the Year, by the Numbers
Metric
Q4 (Apr–Jun '26)
Full Year (FY2026)
Net revenue
$1.27B (reported +1%, organic -1%)
$5.81B (reported -2%, organic -5%)
Prestige segment
$770M (organic -0.5%)
$3.81B (organic -4%)
Consumer Beauty segment
$500M (organic -3%)
$2.00B (organic -7%)
Adjusted gross margin
60.9% (-140bp)
63.0% (-190bp)
Adjusted operating income
$39.5M (prior year $67.7M, -27%)
$627M (prior year $853M, -27%)
Adjusted EBITDA
$93.6M (-26%, margin 7.4%)
$847M (-22%, margin 14.6%)
Adjusted EPS
-$0.02 (estimate -$0.01)
$0.21 (prior year $0.22)
Free cash flow (FCF)
$72.6M (prior year $34.9M)
$348M (prior year $278M)
Prestige (61% of company-wide revenue) held up better: growth in fragrance and color cosmetics offset a skincare decline, leaving Q4 organic sales down only slightly (-0.5%). Consumer Beauty (39%), by contrast, grew in mass skincare but stayed weak in color cosmetics, falling 3% in Q4 and 7% for the full year — a clearly sharper decline than Prestige. By region, the Americas (+$43.5M) and Asia Pacific (+$18.6M, on growth in China, Southeast Asia and travel retail) both grew, while EMEA (-$45.3M) fell on weakness in the Middle East, Germany and Central and Eastern Europe. The company said the Middle East conflict alone weighed on Q4 organic growth by roughly one percentage point.
Q4's Prestige rebound at Coty was driven by fragrance and color cosmetics, not skincare
The Core Insight — Divestitures, Not Operations, Funded the Improvement
Coty's release leaned heavily on how much its financial metrics had improved. Full-year FCF rose to $348M from $278M a year earlier, total debt fell to $3.09B from $3.22B at the end of March, and the net-debt-to-adjusted-EBITDA ratio held at a managed 3.4x. The company said it delivered "more than $250M in productivity and fixed-cost savings in fiscal 2026" to offset inflation and weaker volumes.
But follow the timeline behind that improvement and a different picture emerges. In December 2025 — Coty's fiscal Q3 — the company sold its remaining stake in Wella outright for $750M in cash. Then, around the same time as this earnings release, in July 2026, Coty agreed with Kering to an early exit from the Gucci Beauty license: $250M upon signing, plus up to another $150M (including a conditional $30M) by September 2027, ending the license roughly a year ahead of schedule, on June 30, 2027, instead of its original term. The company said it plans to use these proceeds for "debt reduction, reinvestment in core prestige fragrance and beauty brands, and organizational optimization" — in other words, a meaningful share of the balance-sheet improvement Coty is touting came not from money the business earned, but from money raised by selling parts of the portfolio. And the shrinking isn't done: the company itself flagged that "the early return of the Gucci Beauty license will reduce revenue and profit in fiscal 2028." In effect, Coty is buying cash and debt reduction today at the cost of becoming a smaller company down the road.
The second thing worth flagging is a gap in the guidance. After CEO Sue Nabi stepped down last January following a five-year tenure, Coty named Markus Strobel — a 33-year P&G veteran who most recently led its global Skin & Personal Care division — as Chairman of the Board and Interim CEO, leading the company since January 2026. Yet this earnings release offered guidance only for Q1 FY2027 (organic revenue down a low-to-mid single-digit percentage, adjusted gross margin down 50–100bp) and for H1 (FCF above $300M) — no full-year guidance at all. The company described this as reflecting "completion of the strategic review and the early execution phase of the Coty.Curated strategy," but for a company of Coty's size to skip full-year guidance entirely is unusual. It reads more accurately as a signal that, ahead of naming a permanent CEO, even the company itself isn't confident about how the full year will play out.
Business Impact — a Shrinking Prestige Base, and a Structurally Weak Mass Business
The early Gucci Beauty exit delivers near-term cash but cuts into the Prestige revenue base over the medium term. To offset it, Coty says it will concentrate resources on core fragrance franchises — Burberry, Calvin Klein, Hugo Boss — while building out newer additions such as Marc Jacobs Beauty (makeup) and Swarovski, Etro and Marni (fragrance). Whether these replacement brands can fill the gap Gucci Beauty leaves behind won't be testable until fiscal 2028.
The structural weakness in Consumer Beauty is the other open issue. It fell 3% organically in Q4 and 7% for the full year — a sharper decline than Prestige — with weak mass color cosmetics standing out in particular. Coty said it's simplifying under a program called "Color the Future," cutting SKUs and concentrating resources on a smaller number of proven hits, alongside a Consumer Beauty R&D reorganization and consolidation of global brand-marketing functions. In RIT's view, this reads less like an aggressive plan to grow revenue again than a defensive line drawn to protect profitability inside a shrinking base.
✦RIT's Insights
The first thing that stands out about this release is that a revenue beat and a stock sell-off arrived in the same breath. Chase the headline number alone and "beat estimates" reads as reassurance, but the market read the EPS miss and margin erosion underneath it accurately. Finance and IR teams should, especially in moments like this, separate whether headline figures like FCF and debt improvement came from operating cash generation or from asset-sale proceeds. In a quarter like Coty's, with large divestitures overlapping, judging the trend from operating results alone risks a misread.
The second thing worth flagging is the Wella and Gucci Beauty sales. Trimming the portfolio to cut debt isn't a bad strategy on its own. But these are cards that can only be played once. In RIT's view this deserves closer tracking — having sold Wella and now agreed to exit Gucci Beauty, how many non-core assets does Coty actually have left to sell next? An improvement curve built on divestitures eventually runs out, and after that the company has to win purely on operating strength. For beauty category buyers and MDs, the Gucci Beauty license ending in June 2027 is itself already a working timeline — worth checking in advance how replacement brands like Marc Jacobs Beauty, Swarovski, Etro and Marni plan to distribute domestically when setting prestige fragrance and makeup placement and ordering plans.
Set alongside Estée Lauder's Q4 beat, reported the same week (August 19–20), the two companies' "improvement" is built on entirely different material becomes even clearer. Estée Lauder's came from large-scale layoffs and cost cuts; Coty's came from divestiture cash. Practically speaking, tracking whether each company's organic revenue growth actually improves on its own next quarter is the only way to tell which of the two is a genuine turnaround. Travel-retail/duty-free MDs shouldn't skip past the fact that Coty explicitly named travel retail as one driver of its Asia Pacific growth — worth keeping as evidence that the travel-retail channel still carries real weight within the fragrance category.
Finally, RIT thinks the guidance gap under an interim CEO says something to the wider industry. Korean retailers, too, often struggle to lay out concrete medium-term plans during a CEO transition and end up managing quarter to quarter instead. Coty's case is a useful reference point for how the market reads that vacuum, and for how quickly a permanent leadership decision needs to get made. The moment a permanent CEO is named and full-year guidance returns will be the next real test of whether Coty's recovery is genuine.
